Significance of Levothyroxine Treatment on Serum Lipid in Pregnant Women With Subclinical Hypothyroidism

Yuxi Yang  
Beijing Obstetrics and Gynecology Hospital

Huabing Yuan  
Hebei General Hospital

Xueran Wang  
Beijing Obstetrics and Gynecology Hospital

Zheng Zhang  
Beijing Obstetrics and Gynecology Hospital

Ruixia Liu  
Beijing Obstetrics and Gynecology Hospital

Chenghong Yin (✉ yinchh@ccmu.edu.cn)  
Beijing Obstetrics and Gynecology Hospital

Research Article

Keywords: levothyroxine treatment, serum lipid, subclinical hypothyroidism

Posted Date: January 7th, 2022

DOI: https://doi.org/10.21203/rs.3.rs-1175883/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background

There is no consensus reference range for serum lipid levels during pregnancy. The benefit of levothyroxine (L-T4) on serum lipid levels are unclear among pregnant women with subclinical hypothyroidism (SCH).

Objective

To determine the recommended reference ranges for serum lipid concentrations during pregnancy and effects of L-T4 treatment on serum lipids in pregnant women with SCH.

Design

cohort study.

Methods

A analysis of 20365 women in the first trimester was conducted at Beijing Obstetrics and Gynecology Hospital, Capital Medical University during 2018–2020. After excluding women with adverse pregnancy outcomes, we determined the reference range of serum lipid in the first and third trimesters of pregnancy by using median and quartile to determine appropriate percentiles. Next, we divided into three groups as follows: SCH L-T4 treatment group (n=319), SCH non-intervention group (n=103) and the control group(n=9598).

Results

The recommended reference range for serum lipids in the first trimester of pregnancy should be: TC < 5.33 mmol/L, TG < 1.73 mmol/L, LDL-C < 3.12 mmol/L and HDL-C> 1.1 mmol/L, and in third trimester of pregnancy should be: TC < 8.47 mmol/L, TG < 4.86 mmol/L, LDL-C < 5.3 mmol/L and HDL-C >1.34 mmol/L.

There are significant differences in TC and LDL-C levels between SCH treatment group and SCH non-intervention Group (P=0.043, P=0.046; respectively).

Conclusions

We determine the recommended reference ranges for serum lipid concentrations during pregnancy. TC and LDL-C levels in pregnant women with SCH could improve after L-T4 treatment.

Introduction

Subclinical hypothyroidism (SCH) is defined as the co-presentation of a thyroid-stimulating hormone (TSH) level above the normal range (4.0–10.0 mIU/L) and a serum free thyroxine (FT4) level within the normal range. It is common among women of childbearing age and because of its asymptomatic nature and insidious clinical symptoms, it can be easily missed in clinical practice. The prevalence of SCH during pregnancy is approximately 2%–3%[1]. SCH usually linked to some adverse pregnancy outcomes, such as preterm birth, miscarriage, gestational diabetes mellitus (GDM), and low birth weight[2][3][4][5].

Elevated TSH concentrations in SCH may alter the synthesis and degradation of lipids as well as the function of various enzymes in the lipid metabolism pathway[6]. Key effects of elevated TSH include down-regulation of low-density lipoprotein cholesterol (LDL-C) receptor expression and increased proprotein convertase subtilisin-kexin type 9 (PCSK-9), which together result in higher total cholesterol (TC), LDL-C, and triglyceride (TG), and lower high-density lipoprotein cholesterol (HDL-C)[7][8][9]. Previous study has indicated that non-gestational SCH leads to elevated blood lipid levels with TSH concentrations
Studies had also shown that L-T4 treatment of SCH can improve serum lipid levels, while the research object were all adults, not pregnant women.[11][12][13]

However, there is no consensus reference range for maternal TC, TG, LDL-C, HDL-C levels during gestation. Given the lack of trimester-specific reference values cut-off points, the aim of the present cohort study was to discuss recommended reference ranges for serum lipid concentrations in the first and third trimesters of pregnancy and effects of L-T4 treatment on serum lipid levels in pregnant women with SCH.

**Material And Methods**

*Study design and participants*

This cohort study recruited pregnant women in their first trimester who visited the Beijing Obstetrics and Gynecology Hospital, Capital Medical University between January 2018 and May 2020. All participants answered a questionnaire during early pregnancy (6-13\(^6\) weeks of gestation) about demographic and obstetric characteristics (age, weight, parity, and history of adverse pregnancy outcomes), history of thyroid disease before pregnancy, history of hypertension, and history of diabetes. Written consent has been obtained from each patient or subject after full explanation of the purpose and nature of all procedures used. We continued to follow up these women through the middle and third trimesters of pregnancy until delivery. A total of 20365 women who had complete thyroid examination data and lipid data in the first and third trimesters of pregnancy (6-13\(^6\) weeks of gestation and 28-33\(^6\) weeks of gestation) respectively were enrolled in this study.

We excluded pregnant women with TSH levels < 0.59 mIU/L (n = 3001), mild TSH elevation (TSH concentration between 2.5 and 4.0 mIU/L, n = 2414) and those who had thyroid disease before pregnancy (including thyroid cancer, thyroid nodule, and Hashimoto thyroiditis; n = 328). When all the women had given birth, we also excluded those who had twin or multiple pregnancies (n = 541). Thus, ultimately, 14081 pregnant women were included in this cohort study (Figure 1).

We grouped the women as follows: SCH treatment group (treatment begin at 6-13\(^6\) weeks of gestation, n = 319), SCH non-intervention group (n = 103) and normal thyroid function group (n = 13659).

*Ethical considerations*

Our study protocol was approved by the Ethics Committee of Beijing Obstetrics and Gynecology Hospital, Capital Medical University (Review approval number: 2018-KY-003-01).

*Definitions*

SCH was defined as a normal FT4 level with TSH elevation (4.0–10 mIU/L). The reference values for the normal FT4 range during the first trimester were 11.8–18.4 pmol/L, and these values were determined using Roche Modular Analytics E170 (Roche Diagnostics, Mannheim, Germany). Electrochemiluminescence immunoassays (ADVIA Centaur XP, Siemens Healthcare Diagnostics, Tarrytown, NY, USA) were used to measure the serum FT4 and TSH concentrations. The methods and kits used for the FT4, TSH, and TPOAb tests in our hospital remained the same throughout the study period.

*Serum lipids measurement*

All pregnant women collected venous blood samples after overnight fasting. The concentrations of TC, TG, HDL-C and LDL-C were determined for each sample. Automatic biochemical analyser (AU5400, Beckman, US) were used to measure TC, TG, HDL-C and LDL-C detection kits (Beckman, US). All measurements were measured using continuous monitoring methods with appropriate quality control prior to measurement.

*Adverse pregnancy outcomes*
Adverse pregnancy outcomes included preterm delivery (defined as birth before 37 weeks of gestation), gestational diabetes mellitus (screened for at 24–28 weeks, and diagnosed according to the criteria of the International Association of Diabetes and Pregnancy Study Groups, which require a 75-g oral glucose tolerance test and cut-off values of >5.1 mmol/L, >10.0 mmol/L, and >8.5 mmol/L for fasting blood glucose, blood glucose at 1 h after sugar intake, and blood glucose at 2 h after sugar intake, respectively), gestational hypertension and macrosomia (≥4000 g).

Statistical analysis

All statistical analyses were performed using the SPSS, version 24.0 (SPSS Inc., Chicago, IL, USA). In order to observe the normal trend of serum lipid levels during the first and third trimesters of pregnancy, we excluded those pregnant women with overweight/obesity, gestational hypertension, GDM, preterm birth and macrosomia. Then, using appropriate percentiles and median to descriptive analyses of TC, TG, LDL-C and HDL-C levels for this group (excluded adverse pregnancy outcomes) in first and third trimester of pregnancy. Finally, to establish the lipid reference ranges suitable for the first and third trimesters of pregnancy. Categorical variables were presented as frequency (percentage), and continuous variables were presented as mean (standard deviation [SD]) or median (interquartile range), as appropriate. Analysis of variance was used for normally distributed continuous variables in the multiple subgroup analyses. The Kruskal-Wallis test was used to evaluate continuous variables with non-normal distributions. To compare categorical variables, we used the chi square test or Fisher exact test. The Bonferroni correction was applied for pairwise comparisons. To evaluate the effect of L-T4 treatment on SCH with hyperlipidemia, we used generalized estimation equation. A P value < 0.05 or a P value < 0.05/n in the Bonferroni corrections was considered statistically significant.

Results

Reference range of serum lipid in the first and third trimesters of pregnancy

In total, 20365 pregnant women were included in our study. After excluded GDM (n=3038), overweight/obesity (n=2040), gestational hypertension (n=806), preterm birth (n=867), macrosomia (n=1305), 12309 pregnant women remained. Table 1 presents the median (interquartile range) concentrations and appropriate percentiles for TC, TG, LDL-C and HDL-C in both first and third trimesters of pregnancy. Serum concentrations of TC, TG, LDL-C and HDL-C in the third trimester were significantly higher than those in the first trimester of pregnancy, especially the level of TG increased 2.81 times in the third trimester of pregnancy. The level of TC, TG, LDL-C and HDL-C had 1.57, 2.81, 1.70 and 1.22-fold elevations from the first to third trimester, respectively. Reference range for serum TC, TG and LDL-C in the first and third trimesters of pregnancy ought to less than the 95th percentile and that of HDL-C ought to greater than the 5th percentile[18]. Specifically, the recommended reference range for serum lipids in the first trimester of pregnancy should be: TC < 5.33 mmol/L, TG < 1.73 mmol/L, LDL-C < 3.12 mmol/L and HDL-C > 1.1 mmol/L, and in third trimester of pregnancy should be: TC < 8.47 mmol/L, TG < 4.86 mmol/L, LDL-C < 5.3 mmol/L and HDL-C > 1.34 mmol/L.

Baseline characteristics of SCH pregnant women and control Group

The baseline characteristics of the patients in the L-T4 treatment group (n=319), non-intervention group (n=103) and the control group are shown in Table 2. Control group was defined as normal thyroid function and serum lipid(n=9598).

Of all pregnant women with SCH, 348(82.5%) were tested for TSH concentration during the second trimester(20-23 weeks of gestation) and 304(72.0%) were tested for TSH concentration during the third trimester(28-33 weeks of gestation). No significant differences in BMI, gestational age (GA) at delivery, neonatal birth weight, history of adverse pregnancy outcomes, histories of hypertension, and rate of cesarean section were found among the three groups. The median (interquartile range) age significantly differed between L-T4 treatment group (30 years; 28-33 years), non-intervention group (31.84 years; 3.83), and the control group (30years; 28-33years; P = 0.014). The TSH concentration was significantly higher in the L-T4 treatment group and non-intervention group than in the control group (P < 0.001). In contrast, the FT4 value was significantly higher in
the control group than in the other two groups ($P < 0.001$), though the FT4 value was within the normal range in all three groups.

**Serum lipid levels of SCH pregnant women after L-T4 treatment**

Serum concentrations of TC, TG, LDL-C and HDL-C in SCH pregnant women with hyperlipidemia treatment group (n=319) and non-intervention group (n=103) in the first and third trimester of pregnancy are shown in Table 3. Table 4 shows the effects of L-T4 on pregnant women with SCH who did or did not receive treatment. There are significant differences in TC and LDL-C levels between SCH treatment group and SCH non-intervention Group ($P=0.017$, $P=0.011$; respectively), which indicated that L-T4 treatment could reduce TC and LDL-C levels in pregnant women with SCH. No significant difference in TG and HDL-C concentration between pregnant women with SCH and non-intervention group after L-T4 treatment ($P<0.05$). L-T4 treatment had a significant interaction with age and BMI. Treatment could not directly reduce TG level, but the interaction between treatment and age reduced TG level ($P=0.022$). Identically, treatment could not directly reduce TG and HDL-C levels, but the interaction between treatment and BMI reduced TG and HDL-C levels ($P<0.001$). There are no significant interaction in L-T4 treatment and TSH, FT4 levels ($P>0.05$).

**Discussion**

The current cohort study was performed to evaluate the recommended reference ranges for serum lipid concentrations in the first and third trimesters of pregnancy and effects of L-T4 treatment on serum lipid levels in pregnant women with SCH. Wang et al.\[14\] recommend that the reference values of serum TC, TG and LDL-C in early and middle pregnancy should be less than the 95th percentiles and the reference value of HDL-C should be greater than the 5th percentile. So using the same method, we found that the recommended reference range for serum lipids in the first trimester of pregnancy should be: TC < 5.33 mmol/L, TG < 1.73 mmol/L, LDL-C < 3.12 mmol/L and HDL-C > 1.1 mmol/L, and in third trimester of pregnancy should be: TC < 8.47 mmol/L, TG < 4.86 mmol/L, LDL-C < 5.3 mmol/L and HDL-C > 1.34 mmol/L, which is appropriated for Beijing area. We also found that L-T4 treatment reduced the level of TC and LDL-C in SCH pregnant women.

To date, there are no unified reference ranges evaluate serum lipid in women during pregnancy, our recommended reference range of serum lipid during the various periods of pregnancy is suitable for pregnant women in Beijing area. Furthermore, we also found serum concentrations of TC, TG, LDL-C and HDL-C were significantly higher in pregnant women in the third trimester than they were in the first trimester, especially 2.81-fold TG elevation in third trimester of pregnancy. Previous studies revealed that from the 12th week of pregnancy, TC, TG, LDL-C and HDL-C gradually increase, especially in the second and third trimesters, which consisted with our study\[15\]-[17][18][19][20].

The main finding of our study was that pregnant women with SCH who received L-T4 treatment could improve TC and LDL-C levels compared to non-intervention group ($P=0.043$, $P=0.046$; respectively). As is well-known, SCH patients often present lipid abnormalities, especially elevated TC and LDL-C. Amsterdam Born Children and Their Development cohort study reported that high TG in late pregnancy was independently associated with increased risk of GDM, preeclampsia and premature delivery.\[22\] Thus, the control of serum lipids may benefit SCH patients. However, pregnant women shall not take statins during pregnancy to reduce serum lipid. Most current studies have focused on the reduction of serum lipid in adults with SCH after L-T4 treatment.\[23\] To date, clinical trials have not consistently shown the benefit of L-T4 treatment in improving lipid levels in SCH patients. Kong et al.\[24\] found that L-T4 treatment had no effect on serum lipids and other metabolic indicators in a 6-month randomized trial of female with SCH. Our study is the first in China to report effects of L-T4 therapy on SCH pregnant women with hyperlipidemia.

**Strengths and limitations of this study**

A strength of this study is that all study participants completed a comprehensive questionnaire, which included a detailed review of their medical history, serum lipid tests (including TC, TG, LDL-C and HDL-C) and the results of thyroid function tests
(including T4 and TSH). We also continued to follow up the patients through the middle and third trimesters of pregnancy until delivery.

Nevertheless, our study has several limitations. The main limitation of our study was that the study population was small for some subgroups. Therefore, prospective collection of data from multiple centers is needed to verify the results of this study. In addition, our study was a non-randomized controlled trial, and the quality of evidence for the results was not as good as that of a randomized controlled trial.

In conclusion, the levels of TC, TG, LDL-C and HDL-C have been changing dynamically during pregnancy. Therefore, we determine the recommended reference ranges for serum lipid concentrations in the first and third trimesters of pregnancy. Furthermore, we found that L-T4 treatment could reduce TC and LDL-C levels in pregnant women with SCH. These findings may provide more evidence to support lipid screening during pregnancy, further guidance on the treatment of thyroid disease in pregnant women and inform the development of future guidelines.

Trial registration: Chinese Clinical Trial Register, ChiCTR2100047394. Registered 16 June 2021 - Retrospectively registered, http://www.chictr.org.cn.

**Declarations**

**Consent to participate statement**

Written Informed consent has been obtained from each patient or subject after full explanation of the purpose and nature of all procedures used.

**Ethics approval**

Our study protocol was approved by the Ethics Committee of Beijing Obstetrics and Gynecology Hospital, Capital Medical University (Review approval number: 2018-KY-003-01). All methods were performed in accordance with the relevant guidelines and regulations.

**Consent for publication**

Written consent has been obtained from each patient or subject after full explanation of the purpose and nature of all procedures used.

**Availability of data and materials**

The datasets generated and/or analysed during the current study are available in the ResMan repository, www.medresman.org.cn.

**Competing interests**

The authors have no conflicts of interest to declare.

**Funding**

This work was financially supported by the National Key Research and Development Program of China (No.2016YFC1000101)

**Authors’ contributions**

Yuxi Yang and Huabing Yuan design of the work, interpretation of data and are the major contributor in writing the manuscript. Xueran Wang and Zheng Zhang analyze data of the work; Ruixia Liu and Chenghong Yin substantively revised
the manuscript.

Acknowledgements

Not applicable

References

1. van den Boogaard, E., Vissenberg, R., Land, J.A., van Wely, M., van der Post, J.A.M., Goddijn, M., Bisschop, P.H., 2011. Significance of (sub)clinical thyroid dysfunction and thyroid autoimmunity before conception and in early pregnancy: a systematic review. Hum.Reprod. Update 17, 605–619. DOI:10.1093/humupd/dmr024.

2. Casey BM, Dashe JS, Wells CE, McIntire DD, Byrd W, Leveno KJ, Cunningham FG. Subclinical hypothyroidism and pregnancy outcomes. Obstet Gynecol. 2005;105(2):239–245.

3. Abalovich M, Gutierrez S, Alcaraz G, Maccallini G, Garcia A, Levalle O. Overt and subclinical hypothyroidism complicating pregnancy. Thyroid. 2002;12(1):63–68.

4. Sharmeen M, Shamsunnahar PA, Laita TR, Chowdhury SB. Overt and subclinical hypothyroidism among Bangladeshi pregnant women and its effect on fetomaternal outcome. Bangladesh Medical Research Council bulletin. 2014;40(2):52-57.

5. Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, Grobman WA, Lauberg P, Lazarus JH, Mandel SJ, Peeters RP, Sullivan S. 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid. 2017; 27(3):315–389.

6. Gagnon A, Antunes TT, Ly T, Pongsuwan P, Gavin C, Lochnan HA, et al. Thyroid-stimulating hormone stimulates lipolysis in adipocytes in culture and raises serum free fatty acid levels in vivo. Metabolism 2010;59(4):547–547.

7. Ma S, Jing F, Xu C, Zhou L, Song Y, Yu C, Jiang D, Gao L, Li Y, Guan Q, Zhao J. Thyrotropin and obesity: increased adipose triglyceride content through glycerol-3-phosphate acyltransferase 3. Sci Rep. 2015 Jan 6;5:7633. doi: 10.1038/srep07633. PMID: 25559747; PMCID: PMC4284501.

8. Kwakernaak AJ, Lambert G, Muller Kobold AC, et al. Adiposity blunts the positive relationship of thyrotropin with proprotein convertase subtilisin-kexin type 9 levels in euthyroid subjects [J]. Thyroid, 2013, 23(2): 166-172.

9. Zhou L, Wu K, Zhang L, Gao L, Chen S. Liver-specific deletion of TSHR inhibits hepatic lipid accumulation in mice. Biochem Biophys Res Commun. 2018 Feb 26;497(1):39-45. doi: 10.1016/j.bbrc.2018.01.187. Epub 2018 Feb 6. PMID: 29421660.

10. Zhao M, Yang T, Chen L, et al. Subclinical hypothyroidism might worsen the effects of aging on serum lipid profiles: a population-based case-control study. Thyroid. 2015 May;25(5):485-93. Doi: 10.1089/thy.2014.0219.

11. Abreu IM, Lau E, de Sousa Pinto B, et al. Subclinical hypothyroidism: how to treat or not to treat, that is the question! A systematic review with meta-analysis on lipid profile. Endocr Connect. 2017 Apr;6(3):188-199. Doi: 10.1530/EC-17-0028.

12. Caraccio N, Ferranini E, Monzani F. Lipoprotein profile in subclinical hypothyroidism: response to levothyroxine replacement, a randomized placebo-controlled study. J Clin Endocrinol Metab. 2002 Apr;87(4):1533-8. Doi: 10.1210/jcem.87.4.8378.

13. Kotwal A, Cortes T, Genere N, Hamidi O, Jasim S, Newman CB, Prokop LJ, Murad MH, Alahdab F. Treatment of Thyroid Dysfunction and Serum Lipids: A Systematic Review and Meta-analysis. J Clin Endocrinol Metab. 2020 Dec 1;105(12):dgaa672. doi: 10.1210/clinem/dgaa672.

14. Wang C, Kong L, Yang Y, et al. Recommended reference values for serum lipids during early and middle pregnancy: a retrospective study from China. [J]. Lipids Health Dis. 2018 Oct 31;17(1):246. Doi: 10.1186/s12944-018-0885-3. PMID: 30382875; PMCID: PMC6211477.

15. Bartels Å, Egan N, Broadhurst DI, Khashan AS, Joyce C, Stapleton M, et al. Maternal serum cholesterol levels are elevated from the 1st trimester of pregnancy: A cross-sectional study. J Obstet Gynaecol. 2012;32(8):747–52.
Doi: 10.3109/01443615.2012.714017.

16. Brizzi P, Tonolo G, Esposito F, Puddu L, Dessole S, Maioli M, Milia S. Lipoprotein metabolism during normal pregnancy. *Am J Obstet Gynecol.* 1999;181(2):430–4. doi: 10.1016/S0002-9378(99)70574-0.

17. Piechota W, Staszewski A. Reference ranges of lipids and apolipoproteins in pregnancy. *Eur J Obstet Gynecol Reprod Biol.* 1992;45(1):27–35. doi: 10.1016/0028-2243(92)90190-A.

18. Lippi G, Albiero A, Montagnana M, Salvagno GL, Scevarolli S, Franchi M, Guidi GC. Lipid and lipoprotein profile in physiological pregnancy. *Clin Lab.* 2007;53(3–4):173–7.

19. Hussain F, Latif S, Uddin M, Nessa A. Lipid profile changes in second trimester of pregnancy. *Mymensingh Med J.* 2008;17(1):17–21. PMID: 18285725

20. Ghio A, Bertolotto A, Resi V, Volpe L, Di Cianni G. Triglyceride metabolism in pregnancy. *Adv Clin Chem.* 2011;55:133–53. doi: 10.1016/S0028-2243(92)90190-A.

21. Zhao M, Tang X, Yang T, et al. Lipotoxicity, a potential risk factor for the increasing prevalence of subclinical hypothyroidism? *J Clin Endocrinol Metab.* 2015 May;100(5):1887-94. Doi: 10.1210/jc.2014-3987.

22. Vrijkotte TG, Krukziener N, Hutten BA, et al. Maternal lipid profile during early pregnancy and pregnancy complications and outcomes: the ABCD study. *J Clin Endocrinol Metab.* 2012 Nov;97(11):3917-25. Doi: 10.1210/jc.2012-1295. Epub 2012 Aug 29. PMID: 22933545.

23. Li X, Wang Y, Guan Q, Zhao J, Gao L. The lipid-lowering effect of levothyroxine in patients with subclinical hypothyroidism: A systematic review and meta-analysis of randomized controlled trials. *Clin Endocrinol (Oxf).* 2017 Jul;87(1):1-9. doi: 10.1111/cen.13338. Epub 2017 Apr 24. PMID: 28342184.

24. Kong WM, Sheikh MH, Lumb PJ, Naoumova RP, Freedman DB, Crook M, Doré CJ, Finer N. A 6-month randomized trial of thyroxine treatment in women with mild subclinical hypothyroidism. *Am J Med.* 2002 Apr 1;112(5):348-54. Doi: 10.1016/S0002-9378(99)70574-0.

### Tables

**Table 1. Serum lipid levels of pregnant women in the first and third trimesters of pregnancy**

| Serum lipid levels | Trimester | median (interquartile range) | Percentile (n=12309) |
|--------------------|-----------|-----------------------------|----------------------|
| TC (mmol/L)        | First     | 4.11 (3.72-4.56)            | 2.5% 3.0% 3.19% 3.38% 3.72% 4.11% 4.56% 5.02% 5.33% 5.64% |
|                    | Third     | 6.46 (5.78-7.22)            | 4.58 4.85 5.20 5.78 6.46 7.22 7.98 8.47 8.92 |
| TG (mmol/L)        | First     | 0.92 (0.73-1.17)            | 0.50 0.54 0.61 0.73 0.92 1.17 1.49 1.73 2.00 |
|                    | Third     | 2.76 (2.25-3.44)            | 1.54 1.68 1.88 2.25 2.76 3.44 4.23 4.87 5.57 |
| LDL-C (mmol/L)     | First     | 2.11 (1.77-2.48)            | 1.20 1.35 1.50 1.77 2.11 2.48 2.85 3.12 3.41 |
|                    | Third     | 3.54 (2.91-4.20)            | 1.85 2.09 2.39 2.91 3.54 4.20 4.86 5.30 5.72 |
| HDL-C (mmol/L)     | First     | 1.51 (1.34-1.71)            | 1.03 1.10 1.19 1.34 1.51 1.71 1.91 2.04 2.16 |
|                    | Third     | 1.85 (1.62-2.09)            | 1.25 1.34 1.44 1.62 1.85 2.09 2.34 2.50 2.66 |

Abbreviations: TC: total cholesterol, TG: triglycerides, LDL-C: low-density lipid cholesterol, HDL-C: high-density lipid cholesterol.

**Table 2. Characteristics of pregnant women with SCH who did or did not receive treatment and control subjects**
### Table 3. Serum lipid levels of pregnant women with SCH who did or did not receive treatment

| Serum lipid levels | SCH non-intervention Group | SCH treatment Group |
|--------------------|-----------------------------|---------------------|
| TC (mmol/L)        | first trimester of pregnancy | 4.37(0.77)          | 4.29(3.80-4.81) |
|                    | third trimester of pregnancy | 6.61(1.29)          | 6.42(5.62-7.05) |
| TG (mmol/L)        | first trimester of pregnancy | 1.06(0.85-1.47)     | 1.07(0.81-1.44) |
|                    | third trimester of pregnancy | 2.99(2.49-3.74)     | 2.81(2.32-3.52) |
| LDL-C (mmol/L)     | first trimester of pregnancy | 2.28(0.61)          | 2.20(1.77-2.61) |
|                    | third trimester of pregnancy | 3.64(1.10)          | 3.41(2.70-4.09) |
| HDL-C (mmol/L)     | first trimester of pregnancy | 1.55(1.34-1.77)     | 1.55(1.35-1.75) |
|                    | third trimester of pregnancy | 1.80(1.61-1.97)     | 1.84(0.36) |

**Abbreviations:** TC: total cholesterol, TG: triglycerides, LDL-C: low-density lipid cholesterol, HDL-C: high-density lipid cholesterol.

### Table 4. Effects of L-T4 on pregnant women with SCH who did or did not receive treatment
| Serum lipid levels | group | group*age | group*BMI | group*TSH | group*TSH |
|--------------------|-------|-----------|-----------|-----------|-----------|
|                    | wald $x^2$ | $P$ value | wald $x^2$ | $P$ value | wald $x^2$ | $P$ value | wald $x^2$ | $P$ value | wald $x^2$ | $P$ value |
| TC (mmol/L)        | 5.700 | 0.017     | 10.233    | 0.006     | 2.627     | 0.269     | 1.127     | 0.569     | 2.420     | 0.298     |
| TG (mmol/L)        | 0.274 | 0.600     | 7.608     | 0.022     | 21.548    | <0.001    | 2.192     | 0.334     | 0.519     | 0.771     |
| HDL-C (mmol/L)     | 2.466 | 0.116     | 1.227     | 0.541     | 28.795    | <0.001    | 0.164     | 0.921     | 1.616     | 0.771     |
| LDL-C (mmol/L)     | 6.430 | 0.011     | 5.800     | 0.055     | 0.115     | 0.944     | 0.020     | 0.990     | 2.816     | 0.245     |

Abbreviations: TC: total cholesterol, TG: triglycerides, LDL-C: low-density lipid cholesterol, HDL-C: high-density lipid cholesterol.

The generalized estimation equation was used to compare categorical variables among the two groups.

Dependent variable: TC, TG, HDL-C and LDL-C.

Model: intercept, group, group * age, group * BMI, group * TSH, group * FT4.

**Figures**
20365 women with early-stage pregnancy who were seen consecutively and followed up in Beijing Obstetrics and Gynecology Hospital, Capital Medical University between January 2018 and May 2020

Excluded: pregnant women with TSH < 0.59 mIU/L (n = 3001), pregnant women with TSH 2.5 and 4.0 mIU/L (n = 2414)

Excluded: Twin gestation pregnancies (n=541)

Excluded: personal history of thyroid disease (n=328)

A total of 14081 pregnant women were enrolled

Pregnant women with SCH

Treatment Group (n=319)

Non-intervention Group (n=103)

Pregnant women with normal thyroid function

Excluded: pregnant women with hyperlipidemia (n=4061)

Control Group (n=9598)

Figure 1

Flow chart of patient inclusion